TY - JOUR
T1 - Deep contrastive learning enables genome-wide virtual screening
AU - Jia, Yinjun
AU - Gao, Bowen
AU - Tan, Jiaxin
AU - Zheng, Jiqing
AU - Hong, Xin
AU - Zhu, Wenyu
AU - Tan, Haichuan
AU - Xiao, Yuan
AU - Tan, Liping
AU - Cai, Hongyi
AU - Huang, Yanwen
AU - Deng, Zhiheng
AU - Wu, Xiangwei
AU - Jin, Yue
AU - Yuan, Yafei
AU - Tian, Jiekang
AU - He, Wei
AU - Ma, Weiying
AU - Zhang, Yaqin
AU - Liu, Lei
AU - Yan, Chuangye
AU - Zhang, Wei
AU - Lan, Yanyan
PY - 2026/1/8
Y1 - 2026/1/8
N2 - Recent breakthroughs in protein structure prediction have opened new avenues for genome-wide drug discovery, yet existing virtual screening methods remain computationally prohibitive. We present DrugCLIP, a contrastive learning framework that achieves ultrafast and accurate virtual screening, up to 10 million times faster than docking, while consistently outperforming various baselines on in silico benchmarks. In wet-lab validations, DrugCLIP achieved a 15% hit rate for norepinephrine transporter, and structures of two identified inhibitors were determined in complex with the target protein. For thyroid hormone receptor interactor 12, a target that lacks holo structures and small-molecule binders, DrugCLIP achieved a 17.5% hit rate using only alphaFold2-predicted structures. Finally, we released GenomeScreenDB, an open-access database providing precomputed results for ~10,000 human proteins screened against 500 million compounds, pioneering a drug discovery paradigm in the post-alphaFold era. © 2026 American Association for the Advancement of Science. All rights reserved.
AB - Recent breakthroughs in protein structure prediction have opened new avenues for genome-wide drug discovery, yet existing virtual screening methods remain computationally prohibitive. We present DrugCLIP, a contrastive learning framework that achieves ultrafast and accurate virtual screening, up to 10 million times faster than docking, while consistently outperforming various baselines on in silico benchmarks. In wet-lab validations, DrugCLIP achieved a 15% hit rate for norepinephrine transporter, and structures of two identified inhibitors were determined in complex with the target protein. For thyroid hormone receptor interactor 12, a target that lacks holo structures and small-molecule binders, DrugCLIP achieved a 17.5% hit rate using only alphaFold2-predicted structures. Finally, we released GenomeScreenDB, an open-access database providing precomputed results for ~10,000 human proteins screened against 500 million compounds, pioneering a drug discovery paradigm in the post-alphaFold era. © 2026 American Association for the Advancement of Science. All rights reserved.
UR - https://www.scopus.com/pages/publications/105027090170
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-105027090170&origin=recordpage
U2 - 10.1126/science.ads9530
DO - 10.1126/science.ads9530
M3 - RGC 21 - Publication in refereed journal
C2 - 41505557
SN - 0036-8075
VL - 391
JO - Science
JF - Science
IS - 6781
M1 - eads9530
ER -